Middle East News Digest
SEE OTHER BRANDS

Your daily news update on the Middle East

Middle East News Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.

Press releases published on June 2, 2025

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy ORR is remarkably high in patients with no prior CAR-T or bispecific therapies (84%) as well as …

Bondex’s Native Utility Token $BDXN Secures Listing on Binance Alpha and Futures

Bondex’s Native Utility Token $BDXN Secures Listing on Binance Alpha and Futures

LONDON, UK, June 02, 2025 (GLOBE NEWSWIRE) -- Bondex, the Web3 platform revolutionizing professional trust and credibility, has announced that its native utility token $BDXN will be listed on Binance Alpha, Binance Futures, and other leading exchanges to …

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response (DDR) cancer therapies powered by artificial …

Robex Reports Operational and Financial Results for Q1 2025

Robex Reports Operational and Financial Results for Q1 2025

QUÉBEC CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex" or the "Company") (TSXV: RBX/ASX: RXR) Matthew Wilcox, Managing Director, commented: "The company has had a strong start to 2025, construction continues to advance at Kiniero, and …

Fancamp Announces Appointment of CIO

Fancamp Announces Appointment of CIO

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) is pleased to announce the appointment of Mr. Kit Spring to the position of Chief Investment Officer (“CIO …

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE …

Trust Wallet Launches Buy+, Powered by Binance Connect, to Simplify Crypto Access

Trust Wallet Launches Buy+, Powered by Binance Connect, to Simplify Crypto Access

  Users can buy tokens on BNB Chain, Base and Solana directly with cards, local currency and more - all without leaving the Trust Wallet app. DUBAI, United Arab Emirates, June 02, 2025 (GLOBE NEWSWIRE) -- Trust Wallet, the world’s leading self-custody Web3 …

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48   indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a positive Type-C meeting with FDA for …

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE …

Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors

Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF), is pleased to announce that Mr. Michael Mulberry has been appointed to the board of directors of the …

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 …

Trump Executive Order Fuels Regulatory Shift—Bitcoin Solaris Positioned to Lead Utility-Driven Crypto Era

Trump Executive Order Fuels Regulatory Shift—Bitcoin Solaris Positioned to Lead Utility-Driven Crypto Era

TALLINN, Estonia, June 02, 2025 (GLOBE NEWSWIRE) -- In a sweeping policy move, President Trump has signed an executive order aimed at accelerating the development of a U.S.-led digital asset infrastructure that prioritizes utility, transparency, and …

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a …

Nexxen Announces May 2025 Share Repurchase Program Summary

Nexxen Announces May 2025 Share Repurchase Program Summary

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that during May 2025 the …

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …

Amerigo Announces Board Appointment

Amerigo Announces Board Appointment

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce the appointment of Ignacio Cruz to the Company’s board of directors. Ignacio Cruz is a Civil …

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. …

Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain

Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, …

Dynacor Group Declares June 2025 Dividend

Dynacor Group Declares June 2025 Dividend

MONTRÉAL, June 02, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) ("Dynacor" or the "Corporation") announced its monthly dividend payment for June 2025 in the amount of C$0.01333 per common share which will be payable on June 18, 2025, to …

Groupe Dynacor déclare son dividende pour juin 2025

Groupe Dynacor déclare son dividende pour juin 2025

MONTRÉAL, 02 juin 2025 (GLOBE NEWSWIRE) -- Groupe Dynacor Inc. (TSX : DNG) (« Dynacor » ou la « Société ») a le plaisir d’annoncer la déclaration de son dividende mensuel pour le mois de juin 2025 au montant de 0,01333$CA par action qui sera payé le 18 …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service